Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
Yong-Man KimShin Wha LeeYoung Jae LeeHa Young LeeJong-Eun LeeEun Kyung ChoiPublished in: Journal of gynecologic oncology (2019)
TP53mut ctDNA shows potential as a tumor-specific biomarker for treatment response monitoring in HGSOC. TP53mut ctDNA levels at 3 months post treatment has a significant prognostic utility than that of CA 125.